ESMO pre-"research" news Averumab first-line maintenance therapy for the long-term results of advanced urinary urothelial carcinoma, worth paying attention to!

Abstract number: 1760P

：Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Results from patients with ≥12 mo of treatment in JAVELIN Bladder 100

In the phase 3 JAVELIN Bladder 100 (NCT02603432) trial, avilumab 1L maintenance therapy combined with BSC significantly prolonged the overall survival and progression-free survival of patients with advanced urinary tracheal carcinoma (aUC) without progression after 1L of platinum-containing chemotherapy compared with optimal supportive care (BSC

All of the patients included were patients with unresectable locally advanced or metastatic urothelial carcinoma with no disease progression after 1L platinum-containing chemotherapy

The median follow-up period was 38.

Figure 1 General characteristics of patients

After 12 months of maintenance therapy≥ for aviluzumab, the median overall survival (OS) of the patients did not reach [95% CI 50.

Figure 2 Averuzumab treatment ≥ OS of 12 months

Fig.
3 Aviluzumab treatment ≥ PFS in patients aged 12 months

In the overall averuzumab treatment group (N=344), 67 (19.
5%) had treatment-related adverse events (TRAEs) of grade 3 or higher and 26 (7.
6%) of immune-related adverse events (irAEs)
of grade 3 and above.

Among patients with aviluzumab maintenance therapy ≥ 12 months (n=118), 14 (11.
9%) developed TRAEs of grade 3 and above, and 5 (4.
2%) developed irAEs
of grade 3 and above.

In the JAVELIN Bladder 100 trial, the safety profile of long-term maintenance therapy with aviluzumab 1L was consistent with previous studies of aviluzumab monotherapy, and no new safety risks
were identified after prolonged treatment.

The results of this study further support the feasibility of maintaining treatment with averumab 1L until disease progression in patients with aUC without progression after 1L of platinum-containing chemotherapy
.